{"id":15553,"date":"2021-11-10T12:57:53","date_gmt":"2021-11-10T11:57:53","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=15553"},"modified":"2021-11-10T12:57:53","modified_gmt":"2021-11-10T11:57:53","slug":"gilead-et-kite-acteurs-majeurs-dans-le-domaine-de-la-therapie-cellulaire-elargissent-leur-portefeuille-de-produits-en-developpement-dans-les-hemopathies-malignes","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/gilead-et-kite-acteurs-majeurs-dans-le-domaine-de-la-therapie-cellulaire-elargissent-leur-portefeuille-de-produits-en-developpement-dans-les-hemopathies-malignes\/","title":{"rendered":"Gilead et Kite, acteurs majeurs dans le domaine de la th\u00e9rapie cellulaire, \u00e9largissent leur portefeuille de produits en d\u00e9veloppement dans les h\u00e9mopathies malignes"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:calc( 1240px + 0px );margin-left: calc(-0px \/ 2 );margin-right: calc(-0px \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:0px;--awb-margin-bottom-large:0px;--awb-spacing-left-large:0px;--awb-width-medium:100%;--awb-spacing-right-medium:0px;--awb-spacing-left-medium:0px;--awb-width-small:100%;--awb-spacing-right-small:0px;--awb-spacing-left-small:0px;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><ul>\n<li>L&#8217;\u00e9tude pivot ZUMA-7 de Kite sur la th\u00e9rapie cellulaire CAR T dans le lymphome \u00e0 grandes cellules B r\u00e9fractaire ou en rechute sera pr\u00e9sent\u00e9e au cours d\u2019une session pl\u00e9ni\u00e8re de l&#8217;ASH<\/li>\n<li>Cinq pr\u00e9sentations orales renforcent la place de Kite comme acteur majeur dans le domaine des th\u00e9rapies cellulaires CAR T<\/li>\n<li>Gilead \u00e9tend ses recherches sur la LAM et de nouvelles donn\u00e9es cl\u00e9s sur le magrolimab seront pr\u00e9sent\u00e9es<\/li>\n<\/ul>\n<p>Les donn\u00e9es qui seront pr\u00e9sent\u00e9es \u00e0 la 63e conf\u00e9rence annuelle de l&#8217;American Society of Hematology (ASH) (du 11 au 14 d\u00e9cembre) soulignent de nouveau leur place d\u2019acteur majeur dans le domaine des m\u00e9dicaments et th\u00e9rapies cellulaires CAR T, autoris\u00e9s ou en cours d&#8217;investigation. Gilead et Kite pr\u00e9senteront 21 communications, dont une session pl\u00e9ni\u00e8re et 6 pr\u00e9sentations orales, concernant plusieurs h\u00e9mopathies malignes dont le lymphome \u00e0 grandes cellules B (LBLC), le lymphome non-hodgkinien (LNH), la leuc\u00e9mie aigu\u00eb my\u00e9lo\u00efde (LAM) et le syndrome my\u00e9lodysplasique (SMD).<\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[21],"tags":[],"ppma_author":[442],"class_list":["post-15553","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse","author-marion"],"aioseo_notices":[],"authors":[{"term_id":442,"user_id":2,"is_guest":0,"slug":"marion","display_name":"HematoStat.net (M)","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2024\/01\/favicon-hematoStat.png"},"first_name":"HematoStat.net (M)","last_name":"","user_url":"","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15553","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=15553"}],"version-history":[{"count":0,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/15553\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=15553"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=15553"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=15553"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=15553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}